The estimated Net Worth of Frank R. Oakes is at least $104 Тысяча dollars as of 11 September 2019. Frank Oakes owns over 1,809 units of Edesa Biotech stock worth over $26,941 and over the last 9 years Frank sold EDSA stock worth over $77,219.
Frank has made over 5 trades of the Edesa Biotech stock since 2015, according to the Form 4 filled with the SEC. Most recently Frank sold 7,992 units of EDSA stock worth $57,942 on 18 February 2021.
The largest trade Frank's ever made was selling 7,992 units of Edesa Biotech stock on 18 February 2021 worth over $57,942. On average, Frank trades about 1,300 units every 118 days since 2015. As of 11 September 2019 Frank still owns at least 6,165 units of Edesa Biotech stock.
You can see the complete history of Frank Oakes stock trades at the bottom of the page.
Frank's mailing address filed with the SEC is C/O EDESA BIOTECH, INC., 100 SPY COURT, MARKHAM, A6, L3R 5H6.
Over the last 5 years, insiders at Edesa Biotech have traded over $856,596 worth of Edesa Biotech stock and bought 247,412 units worth $776,447 . The most active insiders traders include Der Velden Peter Lumira Cap..., Pardeep Pardeep Nijhawan Me... и Jennifer M Chao. On average, Edesa Biotech executives and independent directors trade stock every 50 days with the average trade being worth of $73,455. The most recent stock trade was executed by Pardeep Pardeep Nijhawan Me... on 25 March 2024, trading 5,000 units of EDSA stock currently worth $20,000.
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotech executives and other stock owners filed with the SEC include: